openPR Logo
Press release

Up to 30% of women in the GCC and South Asia suffer from infertility resulting from PCOS

03-14-2016 02:55 PM CET | Health & Medicine

Press release from: Informa Life Sciences Exhibitions

Up to 30% of women in the GCC and South Asia suffer from infertility

Dubai, UAE: There is a high incidence of polycystic ovarian syndrome (PCOS) in the Middle East/GCC region mainly due to hereditary and ethnic influences. Approximately up to 20-25% of women in the GCC of Middle Eastern and South Asian ethnicity suffer from PCOS. Experts believe that cases can reach 30% or even higher in the subfertility population in the region. The Obs Gyne Conference aims to tackle the different challenges, treatments and share the latest updates concerning the management of PCOS.

PCOS is the most common endocrine abnormality in women of reproductive age worldwide. It is a genetic disorder with a broad spectrum of clinical and morphological outcomes. It was defined in 1935, and initially called Stein – Leventhal Syndrome, when American gynaecologists Irving F. Stein, Sr., and Michael L. Leventhal associated the presence of ovarian cysts with anovulation. It is an unavoidable disease but can be managed at any age depending on the patient’s needs and expectations at the time.

“PCOS can present in any age especially after weight gain, but can also first present in young adolescent girls. The symptoms associated with this condition vary, but may include some of the following: irregular or absent menstrual periods, hirsutism (increased hair growth), alopecia (female pattern baldness), oily skin & acne, weight related issues, and infertility or difficulty in getting pregnant,” says Dr Salem El Shawarby, Consultant & UK Subspecialist in Reproductive Medicine/ IVF, Director of
Corniche Fertility Centre, Corniche Hospital, Abu Dhabi, UAE.

Dr El Shawarby will discuss the prevention of long-term health hazards in PCOS women at the reproductive health and infertility conference at the Obs-Gyne Exhibition and Congress that will take place March 27-29 at the Dubai International Convention and Exhibition Centre.

Women with PCOS are at greater risk for developing certain complications during pregnancy. In addition, infants born to mothers with PCOS are at higher risk of spending time in the neonatal intensive care unit. Complications of pregnancy associated with PCOS, such as preeclampsia, could be a reason for these risks. Also, conditions common to PCOS like metabolic syndromes such as diabetes and increased androgens may increase the risks affecting infants.

“The best approach to managing PCOS is regular exercise, a healthy balanced food program, and adequate weight control. Lifestyle changes are often initiated as fist line of treatment for improvement of short and long-term outcomes and should precede and/or accompany any pharmacological treatment. Women known to have the condition should not in general delay getting pregnant, and should seek expert fertility advice earlier” highlighted Dr El Shawarby.

Informa Life Sciences Exhibitions, in charge of the healthcare portfolio within Informa's Global Exhibitions division, organises 26 exhibitions yearly covering the Middle East, Africa, Asia, Europe and US market, connecting more than 150,000 healthcare professionals worldwide and offering a range of marketing solutions for companies involved with the healthcare sector. Over 100 congresses take place in parallel with the exhibitions.

Dubai, UAE P.O Box 9248

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Up to 30% of women in the GCC and South Asia suffer from infertility resulting from PCOS here

News-ID: 325848 • Views: 521

More Releases from Informa Life Sciences Exhibitions

3rd edition of MEDLAB Asia Pacific unveils state of the art laboratory innovatio …
Singapore, Singapore: The 3rd MEDLAB Asia Pacific Exhibition and Conference, organised by Informa Life Sciences Exhibitions commenced today and will continue until March 24 2016. It is held at the Sands Expo and Convention Centre, Singapore. The conference programme will featured in total nine CME-accredited conference tracks, accredited by the Singapore Medical Council. The exhibition will feature some of the key industry leaders such as, BioMerieux, Bio-Rad, EUROIMMUN, Siemens, Abbott,
Building Healthcare Exhibition delivers vital platform for decision makers in th …
Dubai, UAE: Building Healthcare Exhibition & Conferences, organised by Informa Life Sciences Exhibitions, will take place 30 May - June 1 2016, at the Dubai International Convention and Exhibition Centre. The exhibition will bring together more than 6,000 leading investors, healthcare CEOs, government representatives, IT decision makers, architects, and more, to discuss the future of healthcare and source the most cutting-edge technologies, products and services available to ensure the
Total Laboratory Automation Key Topic at MEDLAB Asia Pacific 2016
Singapore: Laboratories are under immense pressure to improve turnaround times, reduce human error rates, and improve efficiency while reducing costs. Those are the drivers for today’s automation of most of the clinical laboratories. Laboratory automation stands for the use of technology to minimalize or even eliminate manual handling of equipment and processes. In today’s fast moving healthcare industry, automation becomes crucial in laboratories for handling high volumes of samples at
Better management of insulin resistance needed for UAE women with Polycystic Ova …
Polycystic Ovary Syndrome (PCOS) is one of the most common female hormonal disturbances in the Middle East. The relationship between PCOS and insulin resistance is particularly important here in the UAE where 1 in 5 of the female population suffer from type 2 diabetes and other metabolic syndromes. Professor Samia Farghaly, Head of Academic Department, Primary Healthcare, Dubai Health Authority, Dubai, UAE, will be addressing the issue of ‘Investigation and Management

All 5 Releases


More Releases for PCOS

Global Polycystic Ovary Syndrome (PCOS) Market Research and Forecast 2018-2023
Global polycystic ovary syndrome market size, share, market trends, research and analysis report by diagnosis (ultrasound, pelvic exam, blood test) by treatment (ovarian wedge resection, laparoscopic ovarian drilling, acupuncture) forecast 2018-2023 According to the OMR analysis, the global polycystic ovarian syndrome is growing at a significant rate during 2018-2023. The global polycystic ovarian syndrome has been growing significantly due to initiatives taken by the government authorities regarding early diagnosis of the
Global Polycystic Ovary Syndrome (PCOS) Drugs Market to Reach US$ 1,154.8 Mn by …
According to the latest market report published by Persistence Market Research titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers
Global Polycystic Ovary Syndrome (PCOS) Drugs Market to Reach US$ 1,154.8 Mn by …
According to the latest market report published by Persistence Market Research titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers
Polycystic Ovary Syndrome (PCOS) Drugs Market 2018: BIOCAD, Merck KGaA, AstraZen …
Qyresearchreports include new market research report “2018-2025 Polycystic Ovary Syndrome (PCOS) Drugs Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” to its huge collection of research reports. The global Polycystic Ovary Syndrome (PCOS) Drugs market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017
Polycystic Ovary Syndrome (PCOS) Drugs Market 2018: BIOCAD, Merck KGaA, AstraZen …
Qyresearchreports include new market research report “2018-2025 Polycystic Ovary Syndrome (PCOS) Drugs Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” to its huge collection of research reports. The global Polycystic Ovary Syndrome (PCOS) Drugs market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017
Polycystic Ovary Syndrome (PCOS) Treatment Market Presume to Surge at CAGR 4.6% …
According to the latest market report published by Persistence Market Research titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers